Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00415-020-10045-9 http://scihub22266oqcxt.onion/10.1007/s00415-020-10045-9 C7339100!7339100!32638107     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Neurol 2020 ; 267 (12): 3467-75 Nephropedia Template TP {{tp|p=32638107|t=2020. Impact of COVID-19 on U S and Canadian neurologists? therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices |pdf=|usr=}}{{32638107}} gab.com Text Impact of COVID-19 on U S and Canadian neurologists therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices JO: J Neurol http://www.kidney.de/pget.php?&tw=1&pmid=32638107 #FOAvip Objective: To report the understanding and decision-making of neuroimmunologists and their treatment of patients with multiple sclerosis (MS) during the early stages of the SARS-CoV-2 (COVID-19) outbreak. Methods: A survey instrument was designed and distributed online to neurologists in April 2020. Results: There were 250 respondents (response rate 21.8%). 243 saw?>??=?10 MS patients in the prior 6 months (average 197 patients) and were analyzed further (92% USA, 8% Canada; average practice duration 16 years; 5% rural, 17% small city, 38% large city, 40% highly urbanized). Patient volume dropped an average of 79% (53?11 per month). 23% were aware of patients self-discontinuing a DMT due to fear of COVID-19 with 43% estimated to be doing so against medical advice. 65% of respondents reported deferring?>??=?1 doses of a DMT (49%), changing the dosing interval (34%), changing to home infusions (20%), switching a DMT (9%), and discontinuing DMTs altogether (8%) as a result of COVID-19. Changes in DMTs were most common with the high-efficacy therapies alemtuzumab, cladribine, ocrelizumab, rituximab, and natalizumab. 35% made no changes to DMT prescribing. 98% expressed worry about their patients contracting COVID-19 and 78% expressed the same degree of worry about themselves. ?>?50% believed high-efficacy DMTs prolong viral shedding of SARS-CoV-2 and that B-cell therapies might prevent protective vaccine effects. Accelerated pace of telemedicine and practice model changes were identified as major shifts in practice. Conclusions: Reported prescribing changes and practice disruptions due to COVID-19 may be temporary but could have a lasting influence on MS care. Electronic supplementary material: The online version of this article (10.1007/s00415-020-10045-9) contains supplementary material, which is available to authorized users. Twit Text FOAVip Impact of COVID-19 on U S and Canadian neurologists therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices ????J Neurol http://www.kidney.de/pget.php?&tw=1&pmid=32638107 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32638107 #FOAvip English Wikipedia <ref>{{Cite pmid|32638107}}</ref> Impact of COVID-19 on U S and Canadian neurologists? therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices #MMPMID32638107 Mateen FJ; Rezaei S; Alakel N; Gazdag B; Kumar AR; Vogel A J Neurol 2020[]; 267 (12): 3467-75 PMID32638107show ga Objective: To report the understanding and decision-making of neuroimmunologists and their treatment of patients with multiple sclerosis (MS) during the early stages of the SARS-CoV-2 (COVID-19) outbreak. Methods: A survey instrument was designed and distributed online to neurologists in April 2020. Results: There were 250 respondents (response rate 21.8%). 243 saw?>??=?10 MS patients in the prior 6 months (average 197 patients) and were analyzed further (92% USA, 8% Canada; average practice duration 16 years; 5% rural, 17% small city, 38% large city, 40% highly urbanized). Patient volume dropped an average of 79% (53?11 per month). 23% were aware of patients self-discontinuing a DMT due to fear of COVID-19 with 43% estimated to be doing so against medical advice. 65% of respondents reported deferring?>??=?1 doses of a DMT (49%), changing the dosing interval (34%), changing to home infusions (20%), switching a DMT (9%), and discontinuing DMTs altogether (8%) as a result of COVID-19. Changes in DMTs were most common with the high-efficacy therapies alemtuzumab, cladribine, ocrelizumab, rituximab, and natalizumab. 35% made no changes to DMT prescribing. 98% expressed worry about their patients contracting COVID-19 and 78% expressed the same degree of worry about themselves. ?>?50% believed high-efficacy DMTs prolong viral shedding of SARS-CoV-2 and that B-cell therapies might prevent protective vaccine effects. Accelerated pace of telemedicine and practice model changes were identified as major shifts in practice. Conclusions: Reported prescribing changes and practice disruptions due to COVID-19 may be temporary but could have a lasting influence on MS care. Electronic supplementary material: The online version of this article (10.1007/s00415-020-10045-9) contains supplementary material, which is available to authorized users. äImpact of COVID-19 on U S and Canadian neurologists? therapeutic appr(epmc).pdf DeepDyve Pubget Overpricing